  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Abbreviations, acronyms & symbols                                                                              
  ----------------------------------- ---------------------------------------------------------- --- ----------- ---------------------------------------------------
  AKI                                 = Acute kidney injury                                          ICMP        = Ischemic cardiomyopathy

  AV                                  = Aortic valve                                                 INTERMACS   = Interagency Registry for Mechanically Assisted\
                                                                                                                 Circulatory Support

  BMI                                 = Body mass index                                              LDH         = Lactic acid dehydrogenase

  BTR                                 = Bridge to recovery                                           LV          = Left ventricle

  BTT                                 = Bridge to transplantation                                    LVAD        = Left ventricular assist device

  CABG                                = Coronary artery bypass grafting                              LVEDD       = Left ventricular end-diastolic diameter

  CF                                  = Continuous-flow                                              LVEF        = Left ventricular ejection fraction

  COPD                                = Chronic obstructive pulmonary disease                        MCS         = Mechanical circulatory support

  CPB                                 = Cardiopulmonary bypass                                       MI          = Mitral insufficiency

  CRP                                 = C-reactive protein                                           MV          = Mitral valve

  CVVHD                               = Chronic venovenous hemofiltration                            PCI         = Percutaneous coronary intervention

  DT                                  = Destination therapy                                          RVAD        = Right ventricular assist device

  ECMO                                = Extracorporeal membrane oxygenation                          RVP         = Right ventricular pressure

  EVPP                                = Endoventricular patch plasty                                 s/p         = Status post

  GOLD                                = Global Initiative for Chronic Obstructive Lung Disease       STEMI       = ST-elevation myocardial infarction

  GOT                                 = Glutamate-oxaloacetate transaminase                          TAPSE       = Tricuspid annular plane systolic excursion

  GPT                                 = Glutamate-pyruvate transaminase                              Thr         = Thrombus

  HF                                  = Heart failure                                                TI          = Tricuspid insufficiency

  HTx                                 = Heart transplantation                                        VT          = Ventricular fibrillation

  IABP                                = Intra-aortic balloon pump                                                 

  ICD                                 = Implantable cardioverter defibrillator                                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

INTRODUCTION
============

Due to limited availability of donor organs for heart transplantation, implantation of intracorporal miniaturized left ventricular assist devices (LVAD) became clinical daily routine for treatment of end-stage heart failure (HF), with the number of procedures increasing annually^\[[@r1],[@r2]\]^. HF remains the most common reason for hospital admission in the United States and Western Europe, and therefore, it can be anticipated that the number of LVAD implantations will further increase. Currently, 100% of patients in need for destination therapy, registered in the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS), receive continuous-flow (CF) pumps^\[[@r3],[@r4]\]^. These miniaturized CF pumps improve the outcome of patients with end-stage HF in terms of symptoms, hospitalization, and premature death while awaiting transplantation^\[[@r5]\]^. Patients selected for LVAD implantation usually suffer from significant comorbidities which may (*e.g*., renal failure and lung disease) or may not be associated with the underlying cardiac disease^\[[@r6]\]^. Especially concomitant cardiac conditions, like valve stenosis/regurgitation, coronary heart disease, or right ventricular failure, require additional procedures during LVAD implantation. Here, outcomes were reported for concomitant valve repair/replacement (aortic, mitral, tricuspid), patent foramen ovale closure, or implantation of a temporary right ventricular assist device (RVAD)^\[[@r7]-[@r9]\]^. Another precondition which may be complicating to LVAD surgery is a left ventricular aneurysm in patients with ischemic cardiomyopathy (ICMP) and status post (s/p) transmural myocardial infarction. Here, LVAD insertion is compounded by a thin apical myocardium, and left ventricular thrombus formation is often present^\[[@r10]\]^. To facilitate CF pump insertion and placement and to prevent thromboembolism in such cases, concomitant endoventricular patch plasty (EVPP) (Dor procedure^\[[@r11]\]^) should be taken into consideration. However, these combined procedures are only described anecdotally with documentation of acute and perioperative outcomes^\[[@r12]\]^. We herein describe our experience with combined LVAD and Dor procedures with an emphasis on long-term follow-up.

METHODS
=======

Patients
--------

Between January/2010 and December/2018, 144 patients received LVAD therapy for end-stage HF at our institution. Of those, five patients (5/144, 3.5%) presented with apical aneurysms and received concomitant Dor plasty during LVAD implantation. All five patients presented with ICMP, s/p ST-elevation myocardial infarction, and severely reduced left ventricular ejection fraction. Four patients had a history of multiple percutaneous coronary interventions and one patient underwent multiple coronary artery bypass grafting procedures.

Ventricular Assist Device Implantation and Concomitant Endoventricular Patch Plasty
-----------------------------------------------------------------------------------

In all patients, a HeartWare HVAD (Medtronic, Minneapolis, MN, USA) device was implanted through median sternotomy with support of cardiopulmonary bypass (CPB) to unload the left ventricle. After luxation of the heart, the left ventricular apex was opened. Subsequently, thrombotic material was removed, and the edge of vital myocardium was identified. Here, a reinforcing running 2-0 Prolene (Ethicon Inc., Somerville, NJ, USA) suture buttressed with Teflon felt was performed. Simultaneously, the HVAD ring was sewed in a Vascutek (Terumo Co., Shibuya, Tokyo, Japan) or pericardial patch utilizing a running 3-0 Prolene suture. Then, the patch was attached to the neoapex with interrupted felt-pleged 3-0 Prolene sutures and the patch was furthermore secured by a subsequent performed running 2-0 Prolene suture comprising transmural stitches of vital myocardium. Further procedural steps followed institutional routines including HVAD pump insertion and alignment, tunneling of the driveline, and attaching of the outflow graft to the ascending aorta. Crucial steps of the described procedure are depicted in [Figure 1](#f1){ref-type="fig"}.

![Intraoperative pictures of left ventricular assist device (LVAD) implantation with concomitant Dor plasty. Intraoperative course of patient n. 5: large left ventricular apex aneurysm after median sternotomy (A), opening of the apex (B) and removal of a large thrombus (Thr) (C), adaptation of the LVAD sewing ring to a patch (D), apex reconstruction with the patch (E), and implantation of the LVAD device (F). LV=left ventricle](rbccv-35-04-0477-g01){#f1}

Follow-Up
---------

Baseline, intraprocedural, and follow-up data were collected and entered into a dedicated standardized database. Clinical endpoints were death and heart transplantation. Mean follow-up time was 547.6±473.1 days. Data are presented as absolute numbers and percentages for categorical variables and mean values and standard deviation for continuous variables, unless stated otherwise.

RESULTS
=======

Baseline Demographics
---------------------

Overall, five patients (80% male, 60.4±7.2 years) received concomitant EVPP during LVAD implantation for apical aneurysm and end-stage HF at our institution. Of those, three patients (60%) fulfilled clinical requirements for INTERMACS level 1 or 2, with one patient in need for preoperative temporary mechanical circulatory support (extracorporeal membrane oxygenation therapy). Two patients presented with INTERMACS levels 3 and 4. In three patients, LVAD implantation strategy was bridge to transplantation, and in two patients destination therapy.

Detailed baseline patient demographics are shown in [Table 1](#t1){ref-type="table"}.

###### 

Baseline characteristics of patients who underwent LVAD implantation with concomitant Dor plasty.

                                                     Patient Nº.                                                                                                                                                                                                                                                        
  -------------------------------------------------- ------------------------------------------------------ --------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------ -------------------- ----------
  Age, years                                         66                                                     49                                                  61                                                              67                                                                 59                   60.4±7.2
  Gender, male/female                                Female                                                 Male                                                Male                                                            Male                                                               Male                 4/5 male
  BMI, kg/m^2^                                       26.7                                                   21.6                                                28.9                                                            22.3                                                               24.1                 24.7±3.1
  INTERMACS profile                                  2                                                      1                                                   3                                                               2                                                                  4                    /
  Strategy for LVAD implantation, **✓**/**✘**                                                                                                                                                                                                                                                                           /
      BTT                                            **✘**                                                  **✓**                                               **✓**                                                           **✘**                                                              **✓**                /
      DT                                             **✓**                                                  **✘**                                               **✘**                                                           **✓**                                                              **✘**                /
      BTR                                            **✘**                                                  **✘**                                               **✘**                                                           **✘**                                                              **✘**                /
  Preoperative mechanical ventilation, **✓**/**✘**   **✘**                                                  **✓**                                               **✘**                                                           **✘**                                                              **✘**                /
  Preoperative MCS (ECMO, IABP, Impella)             **✘**                                                  ECMO                                                **✘**                                                           **✘**                                                              **✘**                /
  Further diagnosis                                  s/p STEMI, s/p PCI, COPD, GOLD IV, s/p breast cancer   s/p STEMI, s/p PCI, s/p stroke, diabetes mellitus   s/p STEMI, s/p CABG, re-CABG, re-re-CABG, s/p PCI, s/p stroke   s/p STEMI, s/p PCI, s/p dilative tracheostomy, s/p alcohol abuse   s/p STEMI, s/p PCI   /

BMI=body mass index; BTR=bridge to recovery; BTT=bridge to transplantation; CABG=coronary artery bypass grafting; COPD=chronic obstructive pulmonary disease; DT=destination therapy; ECMO=extracorporeal membrane oxygenation; GOLD=Global Initiative for Chronic Obstructive Lung Disease; IABP=intra-aortic balloon pump; INTERMACS=Interagency Registry for Mechanically Assisted Circulatory Support; LVAD=left ventricular assist device; MCS=mechanical circulatory support; PCI=percutaneous coronary intervention; s/p=status=post; STEMI=ST-elevation myocardial infarction

Preoperative Laboratory and Echocardiographic Findings
------------------------------------------------------

Preoperatively, patients presented with moderate signs of end-organ damage in advanced HF with a mean creatinine value of 1.3±0.6 mg/dl and a glutamic oxaloacetic transaminase of 113.6±191.2 U/l.

Echocardiography revealed a preoperative left ventricular ejection fraction of 16.2±5.1% and no precursors of impaired right ventricular function with a tricuspid annular plane systolic excursion of 17.0±4.5 mm, a right ventricular pressure of 45.2±6.4 mmHg, and a tricuspid insufficiency ≥ moderate in only one patient (1/5, 20%).

Apical aneurysms presented with a diameter between 75 and 98 mm, with left ventricular end-diastolic diameters between 44 and 70 mm. One patient with an apical aneurysm of 98 mm presented an extremely thin myocardial wall of the left ventricular apex in preoperative echocardiography, and LVAD implantation with concomitant EVPP was performed as an emergency procedure due to risk of rupture.

Representative preoperative echocardiographic images of apical aneurysms are shown in [Figure 2](#f2){ref-type="fig"}.

![Preoperative transthoracic echocardiography with depiction of large left ventricular apex aneurysms in patients prior to left ventricular assist device implantation with concomitant Dor plasty. Five-chamber view of patient n. 1 with a left ventricular apex aneurysm of 87 mm (A), fourchamber view of patient n. 5 with a left ventricular apex aneurysm of 98 mm and impending rupture (B), and 3D left ventricular apex reconstruction of patient n. 4 with a septolateral diameter of 75 mm (C, D). AV=aortic valve; LV=left ventricle; MV=mitral valve](rbccv-35-04-0477-g02){#f2}

Detailed preoperative laboratory and echocardiographic findings are summarized in [Table 2](#t2){ref-type="table"}.

###### 

Periprocedural laboratory, echocardiographic, and intraoperative characteristics of patients who underwent LVAD implantation with concomitant Dor plasty.

                                         Patient No.                                                   
  -------------------------------------- ------------- ------- ------- ------- ----------------------- -------------
  Laboratory                                                                                            
      Creatinine, mg/dl                  0.9           2.0     0.9     1.8     0.8                     1.3±0.6
      Hemoglobin, g/dl                   9.2           9.1     10.9    13.9    10.6                    10.7±1.9
      GOT, U/l                           13            44      29      455     27                      113.6±191.2
      GPT, U/l                           20            34      47      80      63                      48.8±23.6
      Lactate, mmol/l                    1.5           2.4     2.1     2.8     1.1                     1.9±0.7
      CRP, mg/l                          5             82      9       47      24                      33.4±31.8
      LDH, U/l                           165           235     226     123     319                     213.6±74.7
  Echocardiography                                                                                      
      LVEF, %                            15            12      25      14      15                      16.2±5.1
      LVEDD, mm                          66            70      64      68      44                      62.4±10.5
      Apical aneurysm diameter, mm       87            98      77      75      98, impending rupture   84.3±10.6
      MI ≥ grade 2, **✓**/**✘**          **✘**         **✓**   **✘**   **✘**   **✘**                   /
      TI ≥ grade 2, **✓**/**✘**          **✘**         **✘**   **✘**   **✘**   **✓**                   /
      RVP, mmHg                          47            55      44      42      38                      45.2±6.4
      TAPSE, mm                          23            12      16      20      14                      17.0±4.5
      Procedure time, min                305           335     380     260     435                     343.0±67.5
  CPB time, min                          180           195     302     139     224                     208.0±60.8
  Cross-clamp time, min                  0             120     0       0       0                       /
  Need for temporary RVAD, **✓**/**✘**   **✘**         **✘**   **✘**           **✘**                   0/5**✓**

CPB=cardiopulmonary bypass; CRP=C-reactive protein; GOT=glutamate-oxaloacetate transaminase; GPT=glutamate-pyruvate transaminase; LDH=Lactic acid dehydrogenase; LVAD=left ventricular assist device; LVEDD=left ventricular end-diastolic diameter; LVEF=left ventricular ejection fraction; MI=mitral insufficiency; RVAD=right ventricular assist device; RVP=right ventricular pressure; TAPSE=tricuspid annular plane systolic excursion; TI=tricuspid insufficiency

Periprocedural Data
-------------------

Mean operation time was 343.0±67.5 min with use of CPB in all cases, with a mean time of 208.0±60.8 min. Cross-clamping of the ascending aorta was performed in one patient. In no case concomitant valve procedures were performed. Also, no planned or unplanned implantation of temporary RVAD was necessary. In all patients, intraoperative echocardiography presented midventricular and coaxial alignment of the LVAD inflow cannula at the end of the procedure.

Clinical Outcome Data
---------------------

LVAD implantation success and 30-day survival were 100% (5/5) with no pump thrombosis or major bleedings (including rethoracotomies) in acute follow-up. In two patients, dilative tracheostomy was performed due to respiratory failure with ventilation times of 232 and 790 hours. Both patients were weaned successfully from mechanical ventilation. Chronic venovenous hemofiltration with a duration of 30 days was necessary in one patient with a preoperative creatinine of 2.0 mg/dl.

In long-term follow-up, one patient was lost on postoperative day 98 due to intentional disconnection of the driveline by the patient. One patient underwent orthotopic heart transplantation on postoperative day 630. Three patients are still on device, with gastrointestinal bleedings in two patients. Moreover, one acute kidney injury occurred during follow-up and one patient presented three consecutive pump thromboses, which were successfully managed by lysis therapy. Quarterly performed echocardiography presented stable, coaxial, and midventricular position of the inflow cannula in all patients. Also, flow and revolutions per minute measurements showed steady values.

Detailed outcome data are summarized in [Table 3](#t3){ref-type="table"}.

###### 

Acute outcomes and follow-up of patients who underwent LVAD implantation with concomitant Dor plasty.

                                           Patient No.                                                                                                                                                                   
  ---------------------------------------- -------------------------------- --------------------------------- ------------------------------------------------ ---------------------------------------- ---------------- -------------
  LVAD implantation success, **✓**/**✘**   **✓**                            **✓**                             **✓**                                            **✓**                                    **✓**            5/5**✓**
  30-day follow-up, LVAD, **✓**/**✘**                                                                                                                                                                                     
      Pump thrombosis                      **✘**                            **✘**                             **✘**                                            **✘**                                    **✘**            0/5**✓**
      Major bleeding                       **✘**                            **✘**                             **✘**                                            **✘**                                    **✘**            0/5**✓**
      Dilative tracheostomy                **✘**                            **✘**                             **✓**                                            **✓**                                    **✘**            2/5**✓**
      Ventilation time, hours              9                                18                                232                                              790                                      2                210.2±338.2
      CVVHD                                **✘**                            **✓**                             **✘**                                            **✘**                                    **✘**            1/5**✓**
      Duration of CVVHD, days              /                                30                                /                                                /                                        /                /
  30-day survival, **✓**/**✘**             **✓**                            **✓**                             **✓**                                            **✓**                                    **✓**            5/5**✓**
  Follow-up time, days                     540                              630                               1290                                             98                                       180              547.6±473.1
  Outcome at follow-up                     Alive, on LVAD                   Alive, s/p HTx                    Alive, on LVAD                                   Deceased                                 Alive, on LVAD   /
  Complications during follow-up           AKI, gastrointestinal bleeding   Epistaxis, VF, ICD implantation   Gastrointestinal bleeding, 3\' pump thrombosis   Intentional disconnection of driveline   /                /

AKI=acute kidney injury; CVVHD=chronic venovenous hemofiltration; HTx=heart transplantation; ICD=implantable cardioverter defibrillator; LVAD=left ventricular assist device; VT=ventricular fibrillation

DISCUSSION
==========

The main findings of the herein conducted study are: (I) LVAD implantation with concomitant Dor procedure is feasible, safe, and occasionally performed in patients with ICMP, (II) no adverse events associated with additional EVPP during LVAD implantation were found in acute or long-term follow-up, (III) once midventricular and coaxial alignment of the inflow cannula is achieved by implantation of the LVAD into the neoapex, pump position is maintained as suggested by our quarterly performed echocardiography, and (IV) prolongation of procedure and CPB time is acceptable in our presented cases and these combined procedures can be performed without cross-clamping in most patients.

Major advantages of a concomitant EVPP during LVAD implantation were already described^\[[@r12]-[@r14]\]^. Despite different reported techniques, prevention of thromboembolism by removal of thrombotic material from the former apex and more stable placement of the pump with coaxial and midventricular positioning of the inflow cannula towards the mitral valve are considered to be facilitated by EVPP. The herein described experience confirms these assumptions. Especially in preposterous dilated aneurysms (like the herein described 98 mm aneurysm with impending rupture) of the left ventricular apex, placement of an LVAD pump is not feasible. With the described technique including excision of thin myocardial wall, identification of vital myocardium, and removal of thrombotic material, shaping of an adequate neoapex for stable pump placement was feasible in all patients. Durability of this solution is of special importance in this scenario and preserved cannula position was confirmed in all patients during echocardiographic follow-up examinations. However, larger patient cohorts are needed before general recommendations regarding EVPP techniques can be made. Also, removal of thrombotic material was effective in the herein described patient cohort. Despite omission of cross-clamping in 80% of the patients, no strokes or pump failure occurred during follow-up. One patient presented with recurrent episodes of pump thromboses, which were treated by lysis therapy and are most likely not connected to preexisting thrombotic material in the left ventricle, since the first pump thrombosis occurred on postoperative day 560. The patient is now event free for 370 days. In the herein reported follow-up, so far the longest for these combined procedures, no events were seen connected to EVPP, which is further corroborating the safety and feasibility of the LVAD and EVPP approach in the instance of left ventricular apical aneurysm. Documented events were mainly bleeding and renal and respiratory failures. These complications were described extensively for patients with end-stage HF undergoing LVAD implantation^\[[@r15],[@r16]\]^ and are not attributable to the performed Dor plasty.

CONCLUSION
==========

In conclusion, LVAD implantation with concomitant EVPP procedural is safe and feasible in patients with end-stage HF, ICMP, and apical aneurysms, facilitates pump placement by building a stable neoapex, and does not affect outcomes in terms of occurrence of acute and long-term events. These findings have to be confirmed in larger patient cohorts before general recommendations can be made.
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